FM 101
Alternative Names: FM-101Latest Information Update: 02 Oct 2021
At a glance
- Originator Femta Pharmaceuticals
- Class Antirheumatics; Monoclonal antibodies
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Crohn's disease; Multiple myeloma; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Crohn's-disease in USA (SC)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (SC)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (SC)